Your browser doesn't support javascript.
loading
The Parity Paradigm: Can Legislation Help Reduce the Cost Burden of Oral Anticancer Medications?
Kircher, Sheetal M; Meeker, Caitlin R; Nimeiri, Halla; Geynisman, Daniel M; Zafar, S Yousuf; Shankaran, Veena; de Souza, Jonas; Wong, Yu-Ning.
Afiliação
  • Kircher SM; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA. Electronic address: skircher@nmff.org.
  • Meeker CR; Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA.
  • Nimeiri H; Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.
  • Geynisman DM; Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA.
  • Zafar SY; Duke Cancer Institute, Durham, NC, USA.
  • Shankaran V; Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • de Souza J; University of Chicago, Chicago, IL, USA.
  • Wong YN; Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA.
Value Health ; 19(1): 88-98, 2016 Jan.
Article em En | MEDLINE | ID: mdl-26797241
ABSTRACT
Over the last decade, there has been increased development and use of oral anticancer medications, which sometimes leads to high cost sharing for patients. Drug parity laws require insurance plans to cover oral anticancer medications with the same cost sharing as intravenous/injected chemotherapy or have a capped limit on out-of-pocket costs. There are currently 36 enacted state laws (plus the District of Columbia) addressing drug parity, but no federal laws. In this policy perspective piece, we discuss the history, opportunities, and limitations of drug parity laws in oncology. We also discuss the implications of provisions of the Affordable Care Act and other proposed policy reforms on financing oral chemotherapy.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Custo Compartilhado de Seguro / Cobertura do Seguro / Honorários Farmacêuticos / Seguro Saúde / Antineoplásicos Tipo de estudo: Health_economic_evaluation / Prognostic_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Custo Compartilhado de Seguro / Cobertura do Seguro / Honorários Farmacêuticos / Seguro Saúde / Antineoplásicos Tipo de estudo: Health_economic_evaluation / Prognostic_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2016 Tipo de documento: Article